早期检测喘:探索症状成年人的炎症生物标志物与正常的螺旋计
Jérémy Laroche1, Marie-Ève Boulay1, Ariane Lechasseur1
1Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec, QC, Canada.
Journal of asthma and allergy
|December 10, 2025
概括
关键的T2炎症生物标志物不能可靠地表明成年人患有呼吸道症状和正常的呼吸量测试的早期喘. 需要对空气道采样进行进一步的研究,以了解它们在喘发展中的作用.
科学领域:
- 呼吸系统医学 呼吸系统医学
- 免疫学 免疫学 免疫学
- 生物标志物发现发现
背景情况:
- 喘发作包括T2 (类型2) 炎症,即使在早期阶段.
- 识别早期喘指标对于及时干预和改善结果至关重要.
研究的目的:
- 评估T2炎症生物标志物在成年人呼吸系统症状和正常的螺旋计.
- 将这些生物标志物与临床表现联系起来,以早期检测喘.
主要方法:
- 对128名加拿大成年人的回顾性观察研究.
- 通过ELISA/多重测定测量血/血清生物标志物 (IL-4,IL-5,IL-13,IL-25,IL-33,eotaxin,eotaxin-3,TARC,periostin,TNF-α) 的测量.
- 通过使用PC20,唾液乙素和FeNO.定义的呼吸道高响应性 (AHR) 和T2炎症.
主要成果:
- 35%的参与者患有T2气道炎症;生物标志物水平各不相同,通常低/无法检测.
- 大多数生物标志物水平在有/没有AHR或T2炎症的人之间没有显著差异.
- 欧素与FEV1/FVC负相关;欧素-3与FeNO正相关.
结论:
- 临床上可访问的T2生物标志物可能无法在这个人群中可靠地检测出早期喘.
- 建议进行纵向跟踪和呼吸道采样,以进一步了解生物标志物在喘发展中的作用.
相关概念视频
Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Asthma-III: Symptoms and Complications
3.2K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
3.2K
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
3.1K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
3.1K
Asthma-I: Introduction
3.3K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.3K
Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K


